Genprex (GNPX) to Release Earnings on Friday

Genprex (NASDAQ:GNPX) is expected to release its resultson Friday, March 27th. Analysts expect Genprex to post earnings of ($13.00) per share for the quarter.

Genprex Price Performance

GNPX stock opened at $1.89 on Wednesday. The business has a fifty day moving average price of $2.22 and a 200 day moving average price of $5.18. Genprex has a fifty-two week low of $1.71 and a fifty-two week high of $55.00. The stock has a market capitalization of $5.90 million, a price-to-earnings ratio of -0.07 and a beta of -0.77.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP raised its position in Genprex (NASDAQ:GNPX) by 11.7% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 340,056 shares of the company’s stock after buying an additional 35,661 shares during the period. Susquehanna International Group LLP owned about 27.20% of Genprex worth $58,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 14.05% of the company’s stock.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.